Header Logo

Jorge Duconge

TitleProfessor
InstitutionUniversity of Puerto Rico
DepartmentPharmaceutical Sciences
AddressUPR-Medical Sciences Campus
School of Pharmacy
PO Box 365067
San Juan PR 00936-5067
Phone(787) 758-2525 ext. 5312
Fax(787) 767-2796
vCardDownload vCard
    Other Positions
    TitleInvestigator (WOC)
    InstitutionVA Caribbean Healthcare System
    DepartmentPharmacy

    TitleCollaborator
    InstitutionHartford Hospital


    Collapse Biography 
    Collapse awards and honors
    1995Summa Cum Laude, University of Havana, Cuba
    1999Best PhD Thesis in Pharmaceutical Sciences, National Council of Scientific Degrees, Cuba
    2002Annual National Prize of Health Sciences, Cuban Public Health Services
    2006 - 2009Teacher of the Year, School of Pharmacy, UPR-MSC
    2007Grant#5P20RR01112, Clinical Research Center infrastructure initiative Pilot Projects Award (RCRII), NIH
    2008Grant#5G11HDO46326, EARDA Program, NICHD, NIH
    2008 - 2011RCMI Mentorship Award, UPR-MSC RCMI Program; NCRR, NIH
    2011 - 2014Grant#HL110393, PGt of Warfarin in Puerto Rican Patients using a Physiogenomics Approach (SC2), NHLBI, NIH
    20132013 ASHP Foundation Literature Award , American Society of Health-System Pharmacists (ASHP)
    2014 - 2018Grant#HL123911, Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics (SC1), NHLBI, NIH
    2017 - 2022Grant#U54MD007600/5318, Adopting a Precision Medicine Paradigm in Puerto Ricans on Clopidogrel, RCMI, NIMHD, NIH

    Collapse Overview 
    Collapse overview
    Dr. Jorge Duconge is a Professor of Pharmacokinetics and Pharmacogenomics in the Department of Pharmaceutical Sciences at the School of Pharmacy, University of Puerto Rico Medical Sciences Campus.
    Dr. Duconge obtained a Baccalaureate in Pharmacy, BSc Pharm (1995, Gold Medal Honors List); Master’s degree in Experimental Pharmacology (1997); and a PhD degree (1999) from the School of Pharmacy, University of Havana. He also completed an advanced Residential Program in pharmacokinetics at Cambridge University, UK in 1998; population pharmacokinetics at State University of New York at Buffalo in 2006, and pharmacometrics (University of Auckland in New Zealand, 2003). He has also spent a mini-sabbatical at Hartford Hospital and the Genomas Laboratory of Personalized Health, CT in 2007, receiving hands-on training on DNA-typing. In addition, he completed the Genetic Analysis for Admixture and Epidemiology Studies in Latin American Populations (University of California at San Francisco (UCSF), USA) in 2010 and a hands-on workshop in next generation sequencing at the University of Pittsburgh/ Pittsburgh Supercomputing Center in 2013.
    His research areas include pharmacogenomics, pharmacokinetics, pharmacometrics and kinetics of drug action. From 1999 to 2004, Dr. Duconge headed the Pharmacokinetic Lab, Center for Biological Evaluation and Research in Havana, performing over 34 research projects and receiving 4 research grants. Since 2005 to date, he has completed various pharmacogenetic studies to determine prevalence of multiple pharmacogenes in the Puerto Rican population and their clinical association to medical outcomes. He also developed a novel PGt-guided algorithm to predict optimal warfarin doses in Puerto Ricans and measures of admixture pattern in this minority population. Moreover, a pharmacokinetic study of intermittent intravenous vitamin C infusions at high doses in prostate cancer patients was conducted. Currently, he is working on the physiogenomic analysis of the Caribbean Hispanics in order to infer their population structure and admixture pattern by using physiogenomic and ancestry markers, and also conducting pharmacogenetic association studies and implementing a DNA-guided algorithm for optimal warfarin management and dosing in Caribbean Hispanics. He is the author of more than 50 scientific publications including reviews, book chapters and research articles in peer-reviewed journals.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hernandez-Suarez DF, Melin K, Marin-Maldonado F, Nunez HJ, Gonzalez AF, Gonzalez-Sepulveda L, Rivas-Tumanyan S, Naik H, Ruaño G, Scott SA, Duconge J. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020 Aug 06; 10(8):e038936. PMID: 32764090.
      Citations:    
    2. Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agúndez JAG, Duconge J, Lee MTM, Woodahl EL, Claudio-Campos K, Daly AK, Klein TE, Pratt VM, Scott SA, Gaedigk A. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2020 Jun 29. PMID: 32602114.
      Citations:    Fields:    
    3. Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, Cavallari LH, Marcatto LR, Beasly MT, Perera MA, Limdi NA, Santos PCJL, Kimmel SE, Lubitz SA, Scott SA, Kawai VK, Jorgensen AL, Pirmohamed M. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2020 Jun; 107(6):1420-1433. PMID: 31869433.
      Citations:    Fields:    
    4. Roche-Lima A, Roman-Santiago A, Feliu-Maldonado R, Rodriguez-Maldonado J, Nieves-Rodriguez BG, Carrasquillo-Carrion K, Ramos CM, da Luz Sant'Ana I, Massey SE, Duconge J. Machine Learning Algorithm for Predicting Warfarin Dose in Caribbean Hispanics Using Pharmacogenetic Data. Front Pharmacol. 2019; 10:1550. PMID: 32038238.
      Citations:    
    5. Maldonado MDM, Rosado-González G, Bloom J, Duconge J, Ruiz-Calderón JF, Hernández-O'Farrill E, Vlaar C, Rodríguez-Orengo JF, Dharmawardhane S. Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography-Tandem Mass Spectrometry. ACS Omega. 2019 Nov 05; 4(19):17981-17989. PMID: 31720502.
      Citations:    
    6. Claudio-Campos K, Moneró-Paredes M, Hernández E, Renta J, Duconge J. Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. 2019 08; 20(12):891-902. PMID: 31453773.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Graydon JS, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A, Rodríguez-Maldonado J, Duconge J, Ruaño G. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations. Biomark Med. 2019 06; 13(8):649-661. PMID: 31157538.
      Citations:    Fields:    Translation:Humans
    8. De la Rosa MVG, Santiago R, Romero JM, Duconge J, Monbaliu JC, López-Mejías V, Stelzer T. Solubility Determination and Correlation of Warfarin Sodium 2-Propanol Solvate in Pure, Binary, and Ternary Solvent Mixtures. J Chem Eng Data. 2019 Apr 11; 64(4):1399-1413. PMID: 32536719.
      Citations:    
    9. Melin K, Moon JY, Qi Q, Hernandez-Suarez DF, Duconge J, Hua S, Gonzalez S, Zeng D, Kaplan RC. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. Pharmacogenomics. 2019 01; 20(2):75-83. PMID: 30520344.
      Citations:    Fields:    Translation:Humans
    10. Duconge J, Ruaño G. Preventing the exacerbation of health disparities by iatrogenic pharmacogenomic applications: lessons from warfarin. Pharmacogenomics. 2018 07 01; 19(11):875-881. PMID: 29898627.
      Citations:    Fields:    Translation:Humans
    11. Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J. Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. Pharmgenomics Pers Med. 2018; 11:95-106. PMID: 29922082.
      Citations:    
    12. Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nuñez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6). PMID: 29848980.
      Citations:    Fields:    Translation:HumansPHPublic Health
    13. Hernandez-Suarez DF, Núñez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 03 28; 33(1):49-55. PMID: 29408797.
      Citations: 2     Fields:    Translation:HumansCells
    14. Reynaldo G, Rodríguez L, Menéndez R, Solazabal J, Amaro D, Becquer MA, Colom Y, Gil H, Polo JC, Castañeda G, Jiménez-Vélez B, Duconge J, Fernández-Sánchez EM. . Journal of Pharmacy & Pharmacognosy Research. A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM. 2018; 3(6):179-190. View Publication.
    15. Reynaldo G, Rodríguez L, Menéndez R, Solazábal J, Amaro D, de Los A Becquer M, Colom Y, Gil H, Polo JC, Castañeda G, Jiménez-Vélez B, Duconge J, Fernández-Sánchez EM. A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM. J Pharm Pharmacogn Res. 2018 May-Jun; 6(3):179-190. PMID: 30739984.
      Citations:    
    16. Carlos Martes-Martinez; Cristian Méndez-Sepúlveda; Joel Millán-Molina; Matthew French-Kim; Heriberto Marín-Centeno; Giselle C. Rivera-Miranda; José J. Hernández-Muñoz; Jorge Duconge-Soler. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico. P R Health Sci Journal. 2017; 3(36):165-172.
    17. Encarnación-Medina J, Rodríguez-Cotto RI, Bloom-Oquendo J, Ortiz-Martínez MG, Duconge J, Jiménez-Vélez B. Selective ATP-Binding Cassette Subfamily C Gene Expression and Proinflammatory Mediators Released by BEAS-2B after PM2.5, Budesonide, and Cotreated Exposures. Mediators Inflamm. 2017; 2017:6827194. PMID: 28900313.
      Citations: 1     Fields:    Translation:HumansCells
    18. Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241. PMID: 28675986.
      Citations: 3     Fields:    Translation:HumansCells
    19. Claudio-Campos K, Labastida A, Ramos A, Gaedigk A, Renta-Torres J, Padilla D, Rivera-Miranda G, Scott SA, Ruaño G, Cadilla CL, Duconge-Soler J. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A Candidate Gene Association Study. Front Pharmacol. 2017; 8:347. PMID: 28638342.
      Citations:    
    20. Jiménez-Ramírez FJ, Castro LM, Ortiz C, Concepción J, Renta JY, Morales-Borges RH, Miranda-Massari JR, Duconge J. Role of treatment-modifying MTHFR677C>T and 1298A>C polymorphisms in metformin-treated Puerto Rican patients with type-2 diabetes mellitus and peripheral neuropathy. Drug Metab Pers Ther. 2017 03 01; 32(1):23-32. PMID: 28231061.
      Citations: 2     Fields:    Translation:Humans
    21. Duconge J, Hernandez-Suarez DF. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. Curr Clin Pharmacol. 2017; 12(1):11-17. PMID: 28245774.
      Citations: 2     Fields:    Translation:Humans
    22. Hernandez-Suarez DF, Claudio-Campos K, Mirabal-Arroyo JE, Torres-Hernández BA, López-Candales A, Melin K, Duconge J. Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep. 2016 Oct-Dec; 4(4):2324709616682049. PMID: 28210634.
      Citations: 2     Fields:    
    23. Céspedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, Montané-Jaime LK, Roblejo H, Fariñas H, Campos ML, Ramírez R, Serrano V, Villagrán CI, Peñas-LLedó EM. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics. 2016 10; 17(15):1707-1724. PMID: 27633613.
      Citations:    Fields:    Translation:Humans
    24. Duconge J, Ruaño G. Admixture and ethno-specific alleles: missing links for global pharmacogenomics. Pharmacogenomics. 2016 09; 17(14):1479-82. PMID: 27537834.
      Citations: 1     Fields:    Translation:Humans
    25. Duconge J, Ramos AS, Claudio-Campos K, Rivera-Miranda G, Bermúdez-Bosch L, Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Ruaño G. A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS One. 2016; 11(1):e0145480. PMID: 26745506.
      Citations: 7     Fields:    Translation:Humans
    26. Miranda-Massari JR, Rodríguez-Gómez JR, González MJ, Cidre C, Duconge J, Marín H, Grace K, McLeod HL. Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions. Int J Diabetes Res. 2016; 5(5):92-101. PMID: 28936369.
      Citations:    
    27. Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, García R, Hernández G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther. 2015 Dec; 30(4):239-49. PMID: 26501165.
      Citations: 1     Fields:    Translation:Humans
    28. Duconge J, Ruaño G. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015; 16(15):1685-8. PMID: 26431456.
      Citations: 1     Fields:    Translation:Humans
    29. Duconge J, Cadilla CL, Seip RL, Ruaño G. Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. P R Health Sci J. 2015 Sep; 34(3):175-7. PMID: 26454897.
      Citations: 3     Fields:    Translation:Humans
    30. Claudio-Campos K, Duconge J, Cadilla CL, Ruaño G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metab Pers Ther. 2015 Jun; 30(2):87-105. PMID: 25431893.
      Citations: 5     Fields:    Translation:Humans
    31. Miranda-Massari JR, González MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo MZ, Jiménez Ramirez FJ, Cintrón K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, Vázquez A. [Metabolic correction: a biochemical option against diseases]. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):60-6. PMID: 26434086.
      Citations:    Fields:    Translation:HumansPHPublic Health
    32. Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Martínez V, Duconge J, Aponte A, Ricart CM. Metabolic Correction as a tool to improve diabetes type 2 management. Bol Asoc Med P R. 2015 Apr-Jun; 107(2):54-9. PMID: 26434085.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    33. González MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Cintrón K, Rodríguez-Gómez JR, Rosario G, Ricart C, Santiago-Cornier JA, Zaragoza-Urdaz R, Vázquez A, Hickey S, Jabbar-Berdiel M, Riordan N, Ichim T, Santiago O, Alvarado G, Vora P. Metabolic correction: a functional biochemical mechanism against disease--Part 1: concept and historical background. P R Health Sci J. 2015 Mar; 34(1):3-8. PMID: 25856870.
      Citations: 1     Fields:    Translation:Humans
    34. Miranda-Massari JR, González MJ, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Hickey S, Vázquez A, Berdiel MJ, Cintrón K, Rodríguez-Gómez JR. Metabolic correction: a functional biochemical mechanism against disease--Part 2: mechanisms and benefits. P R Health Sci J. 2015 Mar; 34(1):9-13. PMID: 25856871.
      Citations: 1     Fields:    Translation:Humans
    35. Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez-O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S. Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Feb 15; 981-982:19-26. PMID: 25594952.
      Citations: 4     Fields:    Translation:Animals
    36. Duconge J. J Pharmacogenomics Pharmacoproteomics. Population Heterogeneity and Genomic Admixture: Relevance for Global Pharmacogenetics. 2014; 5(5):e141. View Publication.
    37. Valentín II, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Ruaño G, Duconge J. Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans. P R Health Sci J. 2014 Sep; 33(3):97-104. PMID: 25244877.
      Citations: 4     Fields:    Translation:Humans
    38. Gonzalez MJ, Miranda-Massari JR, Berdiel MJ, Duconge J, Rodríguez-López JL, Hunninghake R, Cobas-Rosario VJ. High Dose Intraveneous Vitamin C and Chikungunya Fever: A Case Report. J Orthomol Med. 2014; 29(4):154-156. PMID: 25705076.
      Citations:    
    39. Bermudez-Bosch LA, Rivera G, Cruz I, Felici M, Ramos A, Duconge J. . American Journal of Hematology. A Proposal for an Individualized Pharmacogenetic-guided warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy. 2014; 89(1):E1. View Publication.
    40. Karla Claudio-Campos K, Orengo-Mercado C, Berrios L, Pagan R, Renta J, Cadilla C, Duconge J. . The FASEB Journal. CYP2C9*8 frequency distribution in Puerto Ricans: implications for warfarin dosing. 2014; 28(1):1141.10.
    41. Ramos AS, Alejandro Y, Vazquez J, Valentin I, Rivera G, Cruz I, Cadilla CL, Renta J, Duconge J. . American Journal of Hematology. Pharmacogenetic-driven Warfarin Dosing Algorithm in Puerto Ricans. 2014; 89(1):E4. View Publication.
    42. Duconge J, Cadilla CL. CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters? Biomark Med. 2013 Dec; 7(6):913-4. PMID: 24266824.
      Citations: 1     Fields:    Translation:Humans
    43. Ramos AS, Alejandro-Cowan Y, Vazquez J, Valentin I, Rivera G, Renta J, Cruz I, Feliu JF, Cadilla CL, Seip R, Ruaño G, Duconge J. J Thrombosis and Thrombolysis. Pharmacogenetic-driven warfarin dosing algorithm in Puerto Rican patients. In: Warfarin Dosing Management/ Abstract J3. Special Issue: Proceedings of the 12th National Conference on Anticoagulant Therapy. 2013; 3(35):417.
    44. Orengo-Mercado C, Nieves B, López L, Vallés-Ortiz N, Renta JY, Santiago-Borrero PJ, Cadilla CL, Duconge J. Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population. J Pharmacogenomics Pharmacoproteomics. 2013 Mar 27; 4(113). PMID: 24040574.
      Citations:    
    45. Ramos AS, Seip RL, Rivera-Miranda G, Felici-Giovanini ME, Garcia-Berdecia R, Alejandro-Cowan Y, Kocherla M, Cruz I, Feliu JF, Cadilla CL, Renta JY, Gorowski K, Vergara C, Ruaño G, Duconge J. Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients. Pharmacogenomics. 2012 Dec; 13(16):1937-50. PMID: 23215886.
      Citations: 9     Fields:    Translation:Humans
    46. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T, Quintero-Del-Rio AI, Ortiz N. The bio-energetic theory of carcinogenesis. Med Hypotheses. 2012 Oct; 79(4):433-9. PMID: 22809841.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    47. Duconge J, Ruaño G. 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics. 2012 Jul; 13(10):1097-100. PMID: 22909196.
      Citations: 1     Fields:    Translation:Humans
    48. Valentin II, Rivera G, Nieves M, Vazquez J, Cruz I, Renta J, Feliu JF, Cadilla CL, Duconge J. American Journal of Hematology. A Pharmacogenetic Safety Profile of Puerto Ricans on Warfarin Therapy. A10. THSNA meeting proceedings. 2012; 87(Suppl. 1):S152.
    49. Duconge J, Escalera O, Korchela M, Ruaño G. Clinical Implications of Genetic Admixture in Hispanic Puerto Ricans: Impact on the Pharmacogenetics of CYP2C19 and PON1, D. Sanoudou (ed.). In: Clinical Applications of Pharmacogenetics, Chapter 7,. 2012; 151-164. View Publication.
    50. Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Ruaño G, Duconge J. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann Pharmacother. 2012 Feb; 46(2):208-18. PMID: 22274142.
      Citations: 8     Fields:    Translation:Humans
    51. Gonzalez MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T. Schedule Dependence in Cancer Therapy: Intravenous Vitamin C and the Systemic Saturation Hypothesis. J Orthomol Med. 2012 Jan 01; 27(1):9-12. PMID: 24860238.
      Citations:    
    52. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo MZ, Duconge J. Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control. Curr Clin Pharmacol. 2011 Nov; 6(4):260-73. PMID: 22082324.
      Citations: 11     Fields:    Translation:Humans
    53. Seip RL, Duconge J, Ruaño G. Genotype-Guided Statin Therapy. In: Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory. A.H.B. Wu and K.T.J. Yeo (eds.). Molecular and Translational Medicine series. Chapter 10; Springer Science & Business Media (Humana Press), LLC, doi: 10.1007/978-1-60761-283-4. 2011; 155-174.
    54. Rodríguez-Vélez R, Ortiz-Rivera OJ, Bower B, Gorowski K, Windemuth A, Villagra D, Kocherla M, Seip RL, D'Agostino D, Vergara C, Ruaño G, Duconge J. Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J. 2010 Dec; 29(4):402-8. PMID: 21261182.
      Citations:    Fields:    Translation:Humans
    55. González MJ, Miranda-Massari JR, Duconge J. Vitamin C and cancer: what can we conclude--1,609 patients and 33 years later: comment on the article by Cabanillas. P R Health Sci J. 2010 Dec; 29(4):410-1; author reply 411-2. PMID: 21261184.
      Citations:    Fields:    Translation:Humans
    56. Duconge J, Ruaño G. The Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics. J Pharmacogenomics Pharmacoproteomics. 2010 Oct 04; 1(101). PMID: 23227441.
      Citations:    
    57. Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Ruaño G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11. PMID: 20488169.
      Citations: 8     Fields:    Translation:Humans
    58. Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010 May; 6(3):409-24. PMID: 20462345.
      Citations: 10     Fields:    Translation:Humans
    59. González MJ, Rosario-Pérez G, Guzmán AM, Miranda-Massari JR, Duconge J, Lavergne J, Fernandez N, Ortiz N, Quintero A, Mikirova N, Riordan NH, Ricart CM. Mitochondria, Energy and Cancer: The Relationship with Ascorbic Acid. J Orthomol Med. 2010; 25(1):29-38. PMID: 23565030.
      Citations:    
    60. Lojo L, Duconge J, Santiago-Borrero PJ. Pediatric Blood & Cancer. Integrating Combinatorial CYP2C9 and VKORC1 Genotypes into Clinical Warfarin Management in Puerto Rican Children with Thrombosis: An Illustrative Cases Study. 2010; 54(6):811-P162.
    61. Ruaño G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Villagra D, Renta J, Holford T, Santiago-Borrero PJ. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics. 2009 Apr; 10(4):565-77. PMID: 19374515.
      Citations: 17     Fields:    Translation:Humans
    62. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics. Ethn Dis. 2009; 19(4):390-5. PMID: 20073138.
      Citations: 7     Fields:    Translation:Humans
    63. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G. For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethn Dis. 2009; 19(4):479-80. PMID: 20077595.
      Citations:    Fields:    Translation:Humans
    64. Duconge J, Cadilla CL, Renta JY, Silén-Rivera P, Piovanetti P, García-Berdecía R, Castro-Rosario LM, Monzón S, Vélez L, Rosas G, Guerra JA, Santiago-Borrero PJ. Prevalence of CYP2C19 gene polymorphisms in the Puerto Rican population: a preliminary report. P R Health Sci J. 2008 Dec; 27(4):357-8. PMID: 19069365.
      Citations: 8     Fields:    Translation:Humans
    65. Duconge J. Applying organ clearance concepts in a clinical setting. Am J Pharm Educ. 2008 Oct 15; 72(5):121. PMID: 19214275.
      Citations: 2     Fields:    Translation:Humans
    66. LaSala A, Bower B, Windemuth A, White CM, Kocherla M, Seip R, Duconge J, Ruaño G. Integrating genomic based information into clinical warfarin (Coumadin) management: an illustrative case report. Conn Med. 2008 Aug; 72(7):399-403. PMID: 18763667.
      Citations: 1     Fields:    Translation:Humans
    67. Ruaño G, Thompson PD, Villagra D, Bower B, Kocherla M, Yazdanpanah G, Seip RL, Windemuth A, White CM, Duconge J, Holford TR, Wu AH. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. Per Med. 2008 May; 5(3):225-232. PMID: 29783498.
      Citations:    Fields:    
    68. Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH. Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008 Mar; 27(1):7-19. PMID: 18450228.
      Citations: 24     Fields:    Translation:Humans
    69. Ducongé J, Merino N, Alvarez D, Beausoleil I, Fernández-Sánchez E, Rodríguez L, Burt AD. Kinetics of monoclonal anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice. P R Health Sci J. 2008 Mar; 27(1):35-41. PMID: 18450231.
      Citations:    Fields:    Translation:HumansAnimals
    70. Duconge J, Miranda-Massari JR, González MJ, Taylor PR, Riordan HD, Riordan NH, Casciari JJ, Alliston K. Vitamin C pharmacokinetics after continuous infusion in a patient with prostate cancer. Ann Pharmacother. 2007 Jun; 41(6):1082-3. PMID: 17519294.
      Citations: 5     Fields:    Translation:Humans
    71. García-Santana MA, Duconge J, Sarmiento ME, Lanio-Ruíz ME, Becquer MA, Izquierdo L, Acosta-Domínguez A. Biodistribution of liposome-entrapped human gamma-globulin. Biopharm Drug Dispos. 2006 Sep; 27(6):275-83. PMID: 16758502.
      Citations: 2     Fields:    Translation:HumansAnimals
    72. Duconge J. The case of biotech-derived product equivalence: much ado about nothing? Curr Clin Pharmacol. 2006 May; 1(2):147-56. PMID: 18666367.
      Citations:    Fields:    Translation:Humans
    73. Ducongé J, Rodríguez-Vera L, Valenzuela C, Alvarez D, Ramírez O, de la Luz-Hernández KR, Rabeza-Legón EY, Casacó A, Fernández-Sánchez E. Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factor after subcutaneous administration in rabbits. Eur J Pharm Biopharm. 2005 Oct; 61(3):142-8. PMID: 16126380.
      Citations: 2     Fields:    Translation:HumansAnimals
    74. Hernández-Bernal F, García-García I, González-Delgado CA, Valenzuela-Silva C, Soto-Hernández R, Ducongé J, Cervantes-Llano M, Blanco-Garcés E, Rodríguez V, García-Vega Y, Bello-Rivero I, Olivera-Ruano L, López-Saura P. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos. 2005 May; 26(4):151-9. PMID: 15799006.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    75. Duconge J, Prats PA, Valenzuela C, Aguilera A, Rojas I, Becquer MA, Alvarez D, Estrada L, Alfonso-Ortíz S, Hardy-Rando E, García-Pulpeiro O, Fernández-Sánchez E. Topical disposition of two strengths of a 125I-rhEGF jelly in rat skin wounds. Biopharm Drug Dispos. 2004 Jul; 25(5):193-201. PMID: 15248188.
      Citations:    Fields:    Translation:HumansAnimals
    76. Ducongé J, Fernández-Sánchez E, Alvarez D. Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm Drug Dispos. 2004 May; 25(4):177-86. PMID: 15108220.
      Citations: 6     Fields:    Translation:HumansAnimals
    77. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Becquer MA, Fernández-Sánchez E. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci. 2004 Feb; 21(2-3):261-70. PMID: 14757498.
      Citations: 1     Fields:    Translation:HumansAnimals
    78. Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva C, Hernandez-Bernal F, Ferrero-Bibilonia J, Soto-Hernandez R, Cervantes-Llano M, Ducongé J, Correa-Fernandez A, Olivera-Ruano L, Lopez-Saura P. Bioequivalence of two recombinant interferon alpha-2b liquid formulations in healthy male volunteers. Drugs R D. 2004; 5(5):271-80. PMID: 15357626.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    79. Duconge J, Fernández-Sánchez E, Macías A, Castillo R, Garcia I, Beausoleil I, Amador JF, Matheu J. Monoclonal anti-EGFreceptor antibody (ior-R3) pharmacokinetic study in tumor bearing nude mice: role of the receptor-mediated endocytosis on drug clearance. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun; 27(2):101-5. PMID: 12064367.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    80. Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fernández-Sánchez E. Disposition and receptor-site binding of (125)I-EGF after topical administration to skin wounds. Biopharm Drug Dispos. 2002 Mar; 23(2):67-76. PMID: 11932961.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    81. Fernandez-Sánchez E, Ducongé J, Castillo R, Garcia I, Beausoleil I, Macías A. Monoclonal anti-epidermal growth factor receptor (ior EGF/r3) antibody pharmacokinetic studies on nude mice I: a radio-receptor analysis applied to drug serum quantification. J Pharm Pharmacol. 2002 Jan; 54(1):59-64. PMID: 11829130.
      Citations: 1     Fields:    Translation:Animals
    82. Morales AA, Ducongé J, Alvarez-Ruiz D, Becquer-Viart ML, Núñez-Gandolff G, Fernández E, Caballero-Torres I, Iznaga-Escobar N. Humanized versus murine anti-human epidermal growth factor receptor monoclonal antibodies for immunoscintigraphic studies. Nucl Med Biol. 2000 Feb; 27(2):199-206. PMID: 10773550.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    83. Morales AA, Núñez-Gandolff G, Pérez NP, Véliz BC, Caballero-Torres I, Ducongé J, Fernández E, Crespo FZ, Veloso A, Iznaga-Escobar N. Freeze-dried formulation for direct 99mTc-labeling ior-egf/r3 MAb: additives, biodistribution, and stability. Nucl Med Biol. 1999 Aug; 26(6):717-23. PMID: 10587113.
      Citations:    Fields:    Translation:HumansAnimals
    84. Morales-Morales A, Ducongé J, Caballero-Torres I, Núñez-Gandolff G, Fernández E, Iznaga-Escobar N. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma. Nucl Med Biol. 1999 Apr; 26(3):275-9. PMID: 10363798.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    85. Iznaga Escobar N, Morales AM, Ducongé J, Torres IC, Fernández E, Gómez JA. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats. Nucl Med Biol. 1998 Jan; 25(1):17-23. PMID: 9466357.
      Citations: 1     Fields:    Translation:HumansAnimals
    Duconge's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (274)
    Explore
    _
    Co-Authors (15)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _